+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Simple Risk Stratification Model for ST-Elevation Myocardial Infarction (STEMI) from the Combination of Blood Examination Variables: Acute Myocardial Infarction-Kyoto Multi-Center Risk Study Group



A Simple Risk Stratification Model for ST-Elevation Myocardial Infarction (STEMI) from the Combination of Blood Examination Variables: Acute Myocardial Infarction-Kyoto Multi-Center Risk Study Group



Plos one 11(11): E0166391



Many mortality risk scoring tools exist among patients with ST-elevation Myocardial Infarction (STEMI). A risk stratification model that evaluates STEMI prognosis more simply and rapidly is preferred in clinical practice. We developed a simple stratification model for blood examination by using the STEMI data of AMI-Kyoto registry in the derivation set (n = 1,060) and assessed its utility for mortality prediction in the validation set (n = 521). We selected five variables that significantly worsen in-hospital mortality: white blood cell count, hemoglobin, C-reactive protein, creatinine, and blood sugar levels at >10,000/μL, <10 g/dL, >1.0 mg/dL, >1.0 mg/dL, and >200 mg/dL, respectively. In the derivation set, each of the five variables significantly worsened in-hospital mortality (p < 0.01). We developed the risk stratification model by combining laboratory variables that were scored based on each beta coefficient obtained using multivariate analysis and divided three laboratory groups. We also found a significant trend in the in-hospital mortality rate for three laboratory groups. Therefore, we assessed the utility of this model in the validation set. The prognostic discriminatory capacity of our laboratory stratification model was comparable to that of the full multivariable model (c-statistic: derivation set vs validation set, 0.81 vs 0.74). In addition, we divided all cases (n = 1,581) into three thrombolysis in myocardial infarction (TIMI) risk index groups based on an In TIME II substudy; the cases were further subdivided based on this laboratory model. The high laboratory group had significantly high in-hospital mortality rate in each TIMI risk index group (trend of in-hospital mortality; p < 0.01). This laboratory stratification model can predict in-hospital mortality of STEMI simply and rapidly and might be useful for predicting in-hospital mortality of STEMI by further subdividing the TIMI risk index.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057044206

Download citation: RISBibTeXText

PMID: 27835698


Related references

Impact of Door-to-Balloon Time in Patients With ST-Elevation Myocardial Infarction Who Arrived by Self-Transport - Acute Myocardial Infarction-Kyoto Multi-Center Risk Study Group. Circulation Journal 81(11): 1693-1698, 2017

A Novel Risk Stratification Model for Patients with Non-ST Elevation Myocardial Infarction in the Korea Acute Myocardial Infarction Registry (KAMIR): Limitation of the TIMI Risk Scoring System. Chonnam Medical Journal 47(1): 20-26, 2011

Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction A simple risk index predicts mortality in both ST and non-ST elevation myocardial infarction. Journal of the American College of Cardiology 41(6 Suppl. A): 365A-366A, 2003

Risk stratification in acute myocardial infarction by early echocardiographic examination comparison with clinical variables. European Heart Journal 9(ABSTR Suppl. 1): 323, 1988

Predictors of acute kidney injury (AKI) in high-risk ST-elevation myocardial infarction (STEMI) patients: A single-center retrospective observational study. Bosnian Journal of Basic Medical Sciences 19(1): 101-108, 2019

Combination of the Killip and TIMI classifications for early risk stratification of patients with acute ST elevation myocardial infarction. Cardiology 117(4): 291-295, 2010

Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 44(4): 783-789, 2004

Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4A simple index that predicts mortality in St-segment elevation myocardial infarction. Journal of the American College of Cardiology 44(4): 783-789, 2004

A risk stratification algorithm for non ST-segment elevation myocardial infarction Result from the 3rd national registry of myocardial infarction. Circulation 104(17 Suppl.): II 696-II 697, 2001

Validation of a multivariate model for risk stratification in acute ST elevation myocardial infarction Results from TIMI 9B. Journal of the American College of Cardiology 33(2 Suppl. A): 396A, 1999

Outcome up to one year following different reperfusion strategies in acute ST-segment elevation myocardial infarction: the Helsinki-Uusimaa Hospital District registry of ST-Elevation Acute Myocardial Infarction (HUS-STEMI). European Heart Journal. Acute Cardiovascular Care 2(4): 371-378, 2013

Improvement of risk-stratification by use of a new combination of Holter variables in survivors of myocardial infarction. Scandinavian Cardiovascular Journal 36(5): 282-286, 2002

Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. Journal of the American College of Cardiology 47(8): 1553-1558, 2006

Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal 160(4): 671-677, 2010

Efficacy of clotinab in acute myocardial infarction trial-ST elevation myocardial infarction (ECLAT-STEMI). Circulation Journal 76(2): 405-413, 2012